跳至主要内容
临床试验/NCT05616377
NCT05616377尚未招募不适用

Survival Benefit of Combination of Local Therapy and Target Therapy for Brain Metastases With EGFR Mutation: A Multicenter Retrospective Study

Sun Yat-sen University0 个研究点目标入组 2,000 人开始时间: 2022年11月20日最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
2,000
主要终点
OS

研究概览

简要总结

The goal of this observational study is to learn about the survival benefit of local therapy combination with target therapy in lung cancer brain metastases with EGFR mutation. The main questions it aims to answer are:

  • Is local therapy performed before or after target therapy would provide survival benefit ?
  • What kind of local therapy combining with target therapy would provide survival benefit, neurosurgical resection or radiotherapy?

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Evidence of pathological diagnosis of primary tumor.
  • Brain metastases confirmed by enhanced magnetic resonance imaging.
  • Gene test indicated that EGFR mutation.
  • Complete clinical information.

排除标准

  • If surgical treatment is accepted, the surgical treatment is not tumor resection, but ventricle puncture, biopsy and other non-tumor reducing surgery.
  • Patients with 2 or more types of tumors.
  • Incomplete clinical information.

结局指标

主要结局

OS

时间窗: From date of first follow-up until the date of documented death from any cause, assessed up to 120 months

Overall survival

次要结局

  • PFS(From date of first follow-up until the date of first documented progression, assessed up to 120 months)

研究者

发起方
Sun Yat-sen University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yonggao Mou

Department of Neurosurgery

Sun Yat-sen University

相似试验